Department of Medicine, University of Washington School of Medicine, Box 356420 Department of Medicine, 1959 NE Pacific Avenue, Seattle, WA, 98195, USA.
Rev Endocr Metab Disord. 2022 Dec;23(6):1305-1322. doi: 10.1007/s11154-022-09752-7. Epub 2022 Oct 11.
In this narrative review, we discuss the evidence about the controversy about the cardiovascular effects of endogenous and exogenous testosterone in men. Prospective cohort studies with follow-up of ~5-15 years generally indicate no association or a possible inverse relationship between serum endogenous testosterone concentrations and composite major cardiovascular events, cardiovascular deaths and overall mortality. Pharmacoepidemiological studies of large databases generally show no association between testosterone therapy and incident major cardiovascular events, and some pharmacoepidemiological studies demonstrate an association with decreased overall mortality. Randomized, placebo-controlled trials indicate that there is no increased incidence of overall major cardiovascular events with 1-3 years of testosterone therapy. These placebo-controlled trials have major limitations including small numbers of participants, short duration of testosterone therapy and follow-up, and lack of systematic adjudication of cardiovascular events. Overall, the evidence indicates that endogenous testosterone concentrations and testosterone therapy at physiological dosages confer no or minimal effects on the incidence of cardiovascular outcomes. There is insufficient evidence to make conclusions about testosterone therapy for patients at high risk of cardiovascular events (e.g., men with recent myocardial infarctions or stroke and men with recurrent idiopathic deep venous thromboses). In general, clinicians should avoid prescribing supraphysiological testosterone therapy to hypogonadal men or men with slightly low to low-normal serum testosterone concentrations and no identified disorder of the hypothalamus-pituitary-testicular axis because of the uncertain cardiovascular risks and the lack of proven health benefits. For most men with bona fide hypogonadism, benefits of testosterone therapy exceed the potential risk of adverse cardiovascular effects.
在这篇叙述性综述中,我们讨论了关于男性内源性和外源性睾丸激素的心血管作用争议的证据。前瞻性队列研究随访时间约为 5-15 年,一般表明血清内源性睾丸激素浓度与复合主要心血管事件、心血管死亡和总死亡率之间没有关联或可能呈负相关。大型数据库的药物流行病学研究一般表明睾丸激素治疗与主要心血管事件的发生之间没有关联,一些药物流行病学研究表明与总死亡率降低有关。随机、安慰剂对照试验表明,睾丸激素治疗 1-3 年不会增加总体主要心血管事件的发生率。这些安慰剂对照试验存在主要局限性,包括参与者人数少、睾丸激素治疗和随访时间短,以及缺乏对心血管事件的系统裁决。总的来说,证据表明内源性睾丸激素浓度和生理剂量的睾丸激素治疗对心血管结局的发生率没有影响或影响极小。对于有高心血管事件风险的患者(例如近期心肌梗死或中风的男性和复发性特发性深静脉血栓形成的男性),尚无足够的证据得出关于睾丸激素治疗的结论。一般来说,由于不确定的心血管风险和缺乏已证实的健康益处,临床医生应避免给患有性腺功能减退症的男性或血清睾丸激素浓度略低至正常低且无明确下丘脑-垂体-睾丸轴紊乱的男性开超生理剂量的睾丸激素治疗。对于大多数有明确性腺功能减退症的男性,睾丸激素治疗的益处超过潜在的不良心血管影响的风险。